EA201100069A1 - Стабильная инъецируемая наноэмульсия доцетакселя - Google Patents

Стабильная инъецируемая наноэмульсия доцетакселя

Info

Publication number
EA201100069A1
EA201100069A1 EA201100069A EA201100069A EA201100069A1 EA 201100069 A1 EA201100069 A1 EA 201100069A1 EA 201100069 A EA201100069 A EA 201100069A EA 201100069 A EA201100069 A EA 201100069A EA 201100069 A1 EA201100069 A1 EA 201100069A1
Authority
EA
Eurasian Patent Office
Prior art keywords
docetexell
stable injectable
nano emulsion
water
nanoemulsion
Prior art date
Application number
EA201100069A
Other languages
English (en)
Inventor
Гаутам Винод Дафтари
Шриканз Аннаппа Паи
Мангеш Маникрао Кулкарни
Original Assignee
Бхарат Сирумс Энд Вэксинс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бхарат Сирумс Энд Вэксинс Лтд. filed Critical Бхарат Сирумс Энд Вэксинс Лтд.
Publication of EA201100069A1 publication Critical patent/EA201100069A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Настоящее изобретение описывает стабильную инъецируемую наноэмульсионную масло-в-воде композицию доцетакселя, имеющую концентрации доцетакселя такие высокие, как 20 мг/мл, которая избегает аллергической реакции и удерживания жидкости. Композиция использует синтетические триглицериды и DSPE PEG-2000, природные фосфатиды, многоатомный спирт и воду для инъекции. В другом варианте осуществления описаны лиофилизованные продукты с добавлением криозащитных средств, которые после воссоздания дают наноэмульсию, подходящую для парентерального введения.
EA201100069A 2008-07-23 2009-07-22 Стабильная инъецируемая наноэмульсия доцетакселя EA201100069A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1565MU2008 2008-07-23
PCT/IN2009/000416 WO2010018596A2 (en) 2008-07-23 2009-07-22 Stable injectable oil-in-water docetaxel nanoemulsion

Publications (1)

Publication Number Publication Date
EA201100069A1 true EA201100069A1 (ru) 2011-10-31

Family

ID=41527728

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100069A EA201100069A1 (ru) 2008-07-23 2009-07-22 Стабильная инъецируемая наноэмульсия доцетакселя

Country Status (13)

Country Link
US (1) US20110275705A1 (ru)
EP (1) EP2317978A2 (ru)
JP (1) JP5635504B2 (ru)
KR (1) KR20110036075A (ru)
CN (1) CN102105134B (ru)
AU (1) AU2009280803B2 (ru)
BR (1) BRPI0916535A2 (ru)
CA (1) CA2731353A1 (ru)
EA (1) EA201100069A1 (ru)
MX (1) MX2011000795A (ru)
NZ (1) NZ590730A (ru)
WO (1) WO2010018596A2 (ru)
ZA (1) ZA201100465B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589901A4 (en) 2002-12-20 2006-08-09 Generipharm Inc INTRACUTANEOUS INJECTION
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CN102309445B (zh) * 2010-07-06 2013-03-27 上海现代药物制剂工程研究中心有限公司 多西他赛静脉注射组合物及其制备方法
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
CN103298747A (zh) 2010-11-15 2013-09-11 阿彻丹尼尔斯米德兰德公司 组合物及其在转化污染物中的用途
US9987226B2 (en) * 2010-12-10 2018-06-05 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
EP2706977B1 (en) * 2011-05-10 2020-03-04 Archer-Daniels-Midland Company Dispersants having biobased compounds
WO2012156999A1 (en) * 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
KR102007057B1 (ko) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. 당뇨병 치료를 위한 제형물
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20150265572A1 (en) * 2012-10-16 2015-09-24 Genspera, Inc. Injectable cancer compositions
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CN103315978B (zh) * 2013-07-12 2014-12-03 上海市第八人民医院 多西紫杉醇干酏剂及其制备方法和应用
EP3024441A4 (en) * 2013-07-25 2017-04-19 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CN104626418B (zh) * 2015-01-27 2016-10-05 天津现代职业技术学院 异型橡胶管用无硅脂型脱模剂
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP3463299A4 (en) * 2016-06-07 2020-01-15 Targagenix, Inc. NANO EMULSION COMPOSITIONS OF TAXOID ACTIVE SUBSTANCES AND METHOD FOR USE THEREOF AGAINST CANCER CELLS AND CANCER STEM CELLS
US10864280B2 (en) * 2016-06-09 2020-12-15 Der-Yang Tien Nanodroplet compositions for the efficient delivery of anti-cancer agents
JP7097593B2 (ja) 2017-03-31 2022-07-08 テクノガード株式会社 薬物を保持した脂肪粒子を含む非水系組成物およびその製造方法
JP7299166B2 (ja) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド 沈殿抵抗性低分子薬物製剤
CN111920782A (zh) * 2019-05-13 2020-11-13 中国医学科学院药物研究所 复合脂质纳米囊组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
TW422706B (en) * 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008058366A1 (en) * 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
WO2008042841A2 (en) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Docetaxel compositions
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
CN100569294C (zh) * 2007-04-13 2009-12-16 西安力邦制药有限公司 一种静脉注射用高稳定长循环脂肪乳载药制剂

Also Published As

Publication number Publication date
WO2010018596A3 (en) 2010-06-24
CN102105134A (zh) 2011-06-22
US20110275705A1 (en) 2011-11-10
AU2009280803A1 (en) 2010-02-18
CN102105134B (zh) 2013-08-14
EP2317978A2 (en) 2011-05-11
MX2011000795A (es) 2011-03-29
AU2009280803B2 (en) 2013-10-31
NZ590730A (en) 2012-10-26
KR20110036075A (ko) 2011-04-06
JP2011529042A (ja) 2011-12-01
WO2010018596A2 (en) 2010-02-18
ZA201100465B (en) 2012-02-29
BRPI0916535A2 (pt) 2015-11-10
JP5635504B2 (ja) 2014-12-03
CA2731353A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
EA201100069A1 (ru) Стабильная инъецируемая наноэмульсия доцетакселя
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
ES2478820T3 (es) Tratamiento de degeneración macular
WO2009111057A3 (en) Fulvestrant formulations
BRPI0801675A2 (pt) partÍculas de pigmento em nanoescala de quinacridona
EA201071421A1 (ru) Анти-flt3 антитела
PE20131166A1 (es) Formulacion de premezcla de dexmedetomidina
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
UY33034A (es) Materiales y métodos para el tratamiento o prevención de enfermedades asociadas al her-3
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
SV2009003208A (es) Composiciones de combustible que contienen farnesano y derivados de farnesano y metodos de preparacion y uso de estas ref. 392767-122012/11836-012-122
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
CO6231001A2 (es) Estabilizacion de vitamina b12
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
PE20141413A1 (es) Formulaciones de anticuerpo y metodos
EA201270050A1 (ru) Нанодисперсия лекарственного средства и способ ее получения
BR112013027086A2 (pt) composto, composição aquosa, composição de emulsão, composição bifásica, método de deslocamento de um material de hidrocarboneto em contato com um material sólido, método de conversão de um ácido de petróleo não refinado em um tensoativo e método de preparação de um composto
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
PE20091964A1 (es) Encapsulacion de agentes biologicamente activos
BR112015032200A2 (pt) conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
BR112019023981A2 (pt) injeção de octreotida